THERAPY OF PATIENTS WITH ANXIETY DISORDERS AND METABOLIC SYNDROME X

  • Olena V. Kaushanska Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Bukovynian State Medical University, Chernivtsi, Ukraine
  • Olena V. Zaliavska Department of Internal Medicine, Clinical Pharmacology, and Occupational Diseases, Bukovynian State Medical University, Chernivtsi, Ukraine
  • Olha M. Nika Department of Nervous Diseases, Psychiatry, and Medical Psychology, Bukovynian State Medical University, Chernivtsi, Ukraine
Keywords: metabolic syndrome, mental disorders, tranquilizers, Spielberger-Khanin scale, Afobazole

Abstract

Objective of the research: to investigate the efficacy and safety of Afobazole in the treatment of adult patients with anxiety disorders and metabolic syndrome X.

Material and methods of research. The study included 60 adult patients (18–65 years) (36 men, 24 women), whose clinical picture revealed mild and moderate forms of neurotic disorders observed in the therapeutic hospital and outpatient service. The main group (30 people) and control group (30 people) were formed on the basis of representativeness by gender and age (χ2emp <χ2krit, p ≤ 0.01). The sample consisted of patients who signed a written informed consent to participate in the study. The average age of the patients in the control group was 44.81 ± 2.17, in the main group ­– 45.13 ± 2.34 (p < 0.01); the average age of onset of mental disorders in the main group was 33.2 ± 3.1 years; in the control group it was 34.1 ± 3.4 years (p < 0.05); the average duration of psychopathological symptoms in the main group was 5.6 ± 0.6 months, in the control group – 5.8 ± 0.3 months (p < 0.05). The duration of treatment equaled 1 month of active therapy (later, the patients were transferred to maintenance therapy outside this study). Afobazole containing 0.01 g of active substance per tablet was used for treatment. The drug was prescribed 3 times a day (morning, afternoon and evening); the dose of the drug was increased: 1–1–2 (number of tablets per administration).

Research results. There were changes in psychometric scaling, i.e. a significant decrease in state (by 57.2 and 42.9%; p ≤ 0.001) and trait (by 23.8 and 23.3%; p ≤ 0, 01) anxiety on the Spielberger–Khanin scale in the main and control groups at the end of treatment. In all groups of patients, we noted complete recovery (38.4%) or a significant improvement (37.9%); for most patients with mild manifestations, complete recovery was observed in 92% of cases. Among patients with moderate manifestations, a good response was recorded in 75% of cases; for the rest, moderate and minimal effects were observed, respectively. The changes in the severity as compared with baseline values were significantly positive (p < 0.05) already after 7 days of Afobazole therapy; similar changes were noted in the indicators of the overall effectiveness of therapy. No positive changes after Afobazole therapy were observed in 3.3% of cases, deterioration was registered in 3.3% of cases, while in the control group these values were 6.6% and 3.3%, respectively. The changes in somatic indicators also had positive trends in the control and main groups – SBP reduced by 11.0% and 18.0%, respectively (p ≤ 0.05); DBP – by 4.4% and 14.9% (p ≤ 0.05).

Conclusion. The therapeutic effect of Afobazole is the reduction of viscero-vegetative manifestations of anxiety disorders, including relief of breathing, normalization of blood pressure and heart rate, reduction of muscle tension and pain, sweating and dizziness.

Author Biographies

Olena V. Kaushanska, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases, Bukovynian State Medical University, Chernivtsi, Ukraine

к-т мед. наук, доцент кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Olena V. Zaliavska, Department of Internal Medicine, Clinical Pharmacology, and Occupational Diseases, Bukovynian State Medical University, Chernivtsi, Ukraine

к-т мед. наук, асистент кафедри внутрішньої медицини, клінічної фар­макології та професійних хвороб, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002

Olha M. Nika, Department of Nervous Diseases, Psychiatry, and Medical Psychology, Bukovynian State Medical University, Chernivtsi, Ukraine

к-т мед. наук, асистент кафедри нервових хвороб, психіатрії та медичної психології, Буковинський державний медичний університет, Театральна пл., 2, м. Чернівці, Україна, 58002.

References

1. Meydan C, Shenhar-Tsarfaty S, Soreq H. MicroRNA Regulators of Anxiety and Metabolic Disorders. Trends Mol. Med. 2016;22(9):798-812. https://doi.org/10.1016/j.molmed.2016.07.001
2. Kraemer F, Ginsberg H, Reaven G. Demonstration of the central role of insulin resistance in type 2 diabetes and cardiovascular disease. Diabetes Care. 2014;37(5):1178-1181. https://doi.org/10.2337/dc13-2668
3. Girvalaki C, Vardavas C, Papandreou C. Trends in metabolic syndrome risk factors among adolescents in rural Crete between 1989 and 2011. Hormones (Athens). 2014;13(2):259-267. https://doi.org/10.1007/bf03401340
4. Inzucchi S, Viscoli C, Young, L. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diabetes Care. 2016;39(10):1684-1692. https://doi.org/10.2337/dc16-0798
5. Martino F, Pannarale G, Puddu P. Is it possible a new definition of metabolic syndrome in childhood? Eur. Rev. Med. Pharmacol. Sci. 2015;19(22):4324-4331.
6. Vishram J, Borglykke А, Andreasen A. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS ONE, 9. 2014. http://dx.doi.org/10.1371/journal.pone.0107294
Published
2021-09-29
How to Cite
Olena V. Kaushanska, Olena V. Zaliavska, & Olha M. Nika. (2021). THERAPY OF PATIENTS WITH ANXIETY DISORDERS AND METABOLIC SYNDROME X. Eastern Ukrainian Medical Journal, 9(3), 262-267. https://doi.org/10.21272/eumj.2021;9(3):262-267